Weight loss peptides and medications
Losing weight is less about willpower than about biology: hunger hormones, blood sugar swings, and metabolism all push back. These articles look at the weight loss peptides and medications researchers study — how they work, what results have been measured, and what a realistic plan looks like alongside food and movement.
Nothing here is a shortcut or a guarantee. Medication is one tool, prescribed only when a licensed provider decides it fits your situation. Every article below is specific about what was measured and in whom.
135 articles on this topic
-
Foods to Avoid on Tirzepatide: A Practical Guide
There is no universal ban list. Smaller portions and fewer fried, high-fat, fizzy, or alcohol-heavy choices may make nausea, reflux, bloating, and fullness easier to manage.
-
Semaglutide and Pancreatitis: What Studies Show
Randomized trials have not shown more acute pancreatitis with semaglutide than with placebo, but the event is rare and remains a prescribing-label warning. Persistent, severe abdominal pain needs prompt medical attention.
-
Tesamorelin for Belly Fat: What the Studies Show
Tesamorelin has reduced visceral abdominal fat in randomized trials, most convincingly in adults with HIV-associated lipodystrophy. That evidence does not make it a general weight-loss drug or a reliable way to shrink the fat just under the skin.
-
Tirzepatide for PCOS: What the Evidence Shows
Early studies connect tirzepatide with weight and metabolic changes in people with PCOS, but the direct evidence is still small. Pregnancy plans and the reason for prescribing matter as much as the diagnosis.
-
Tirzepatide Plateau: Why Weight Loss Slows
A tirzepatide plateau is usually the point where a smaller body and stronger biological pressure to maintain weight balance the medication's effects. A brief stall is not the same thing, and a prescriber should review the pattern before changing treatment.
-
Semaglutide and Pregnancy: What the Evidence Says
Semaglutide is not recommended for routine weight management during pregnancy. The label calls for a two-month gap before planned conception, while early human exposure data remain limited rather than conclusive.
-
Tirzepatide Benefits: What the Trials Show
Tirzepatide benefits are best established for weight reduction and blood-sugar control, with a branded indication for moderate-to-severe sleep apnea in adults with obesity. Heart failure, liver, blood-pressure and lipid findings are promising but narrower.
-
Liraglutide vs Semaglutide: A Clear Comparison
Both are GLP-1 medicines, but liraglutide is usually injected daily and semaglutide weekly. Head-to-head trials show why the treatment goal and dose matter as much as the molecule.
-
Tirzepatide Long-Term Side Effects: 3-Year Data
Three-year weight-management data and four-year cardiovascular data have not revealed a new late safety signal. They also do not tell us what decades of exposure will look like.
-
What Happens When You Stop Taking Tirzepatide?
Appetite suppression fades as tirzepatide clears, and weight regain is common but neither immediate nor inevitable. SURMOUNT-4 shows the difference between stopping and continuing over one year.
-
Peptides for Insulin Resistance: Evidence
The evidence runs from large clinical trials for semaglutide and tirzepatide to animal and observational research for MOTS-c. Those are not interchangeable levels of certainty.
-
Does Semaglutide Cause Muscle Loss?
Semaglutide-related weight loss can include a drop in lean mass, but DXA lean mass is not the same as skeletal muscle. STEP 1 found fat fell faster than lean tissue, improving lean mass as a share of body weight.
-
GLP-1 Drops: What the Absorption Evidence Shows
GLP-1 drops promise a needle-free shortcut, but the delivery system is the whole question. No published human clinical evidence yet shows that sublingual semaglutide drops achieve meaningful absorption or weight-loss efficacy.
-
Does Semaglutide Make You Tired? What Trials Show
Yes, fatigue can happen, though it was reported by a minority of people in STEP trials. The timing and accompanying symptoms help distinguish low intake or dehydration from hypoglycemia or another cause.
-
Semaglutide and Alcohol: What to Know
There is no listed direct interaction between semaglutide and alcohol, but the combination can make nausea, dehydration, low blood sugar, and pancreatitis risk more important.
-
What Happens When You Stop Taking Semaglutide
Appetite commonly returns as semaglutide clears, and some weight regain is likely. Trials show why stopping is better treated as a long-term care decision than as a test of willpower.
-
Does Insurance Cover Tirzepatide? 2026 Guide
Insurance may cover Mounjaro for type 2 diabetes, while Zepbound coverage for obesity or sleep apnea depends on the plan. Compounded tirzepatide is generally self-pay.
-
Tirzepatide vs Retatrutide: How They Compare
Tirzepatide is a dual GIP/GLP-1 agonist with completed phase 3 trials and approved U.S. indications. Retatrutide is an investigational triple agonist with no approved U.S. indication — and that, not potency, is the difference that matters.
-
Is Semaglutide Safe? What the Evidence Shows
Semaglutide has years of trial data and a defined risk profile, but safe is not universal. Eligibility depends on personal history, other medicines, monitoring and exactly what product is dispensed.
-
Tirzepatide Weight Loss Results by Month
In SURMOUNT-1, average weight loss reached 15.0% to 20.9% at 72 weeks, depending on dose. The first month was only the initiation phase, and results varied widely.
Page 6 of 7 · 135 articles